Consensus The Beauty Health Company

Equities

SKIN

US88331L1089

Market Closed - Nasdaq Other stock markets 04:00:05 2024-04-23 pm EDT			5-day change	1st Jan Change
3.22 ^USD	-1.53%		-9.04%	+3.54%

Apr. 10	Beauty Health Names Sheri Lewis as Chief Supply Chain, Operations Officer	MT
Apr. 09	The Beauty Health Company Announces Termination of Brad Hauser as Chief Operating Officer	CI

Evolution of the average Target Price on The Beauty Health Company

Price target over the last 5 years

History of analyst recommendation changes

db5ad87370bfaffc.L1d9H1FPhhAXgDboFXNodY5aKu4tjiVH3qKFuecnYvQ.QQ8ibAN7xV0u6H3adBkJBKMcYb0Y6FQBnfDP9IpQG7gYJxVpMjXrflPfXQ~60a3766e5074d172f29061a00629918f

Analyst Recommendations on The Beauty Health Company

Canaccord Genuity Adjusts Price Target on The Beauty Health to $4 From $3, Maintains Hold Rating	Mar. 14	MT
Stifel Raises Price Target on The Beauty Health to $4 From $3, Maintains Hold Rating	Mar. 13	MT
TD Cowen Adjusts Price Target on The Beauty Health to $4 From $2.50, Maintains Market Perform Rating	Mar. 13	MT
Piper Sandler Adjusts Beauty Health's Price Target to $3 From $2, Maintains Underweight Rating	Mar. 13	MT
Jefferies Downgrades Beauty Health to Hold From Buy, Adjusts Price Target to $1.50 From $11	Nov. 15	MT
Stifel Adjusts Beauty Health's Price Target to $3 From $8, Keeps Hold Rating	Nov. 14	MT
TD Cowen Downgrades Beauty Health to Market Perform From Outperform, Cuts Price Target to $2.50 From $9	Nov. 14	MT
The ideal scenario is becoming reality	Nov. 14
Raymond James Downgrades Beauty Health to Underperform From Market Perform	Nov. 14	MT
William Blair Downgrades Beauty Health to Market Perform From Outperform	Nov. 14	MT
Canaccord Genuity Downgrades Beauty Health to Hold From Buy, Price Target is $2.50	Nov. 14	MT
JPMorgan Downgrades Beauty Health to Underweight From Neutral	Nov. 14	MT
Piper Sandler Downgrades Beauty Health to Underweight From Overweight, Adjusts Price Target to $2 From $12	Nov. 14	MT
Canaccord Genuity Assumes The Beauty Health Company at Buy With $10 Price Target	23-08-25	MT
TD Cowen Adjusts Price Target on The Beauty Health to $9 From $15, Maintains Outperform Rating	23-08-10	MT
DA Davidson Adjusts Price Target on Beauty Health to $16.50 From $35, Maintains Buy Rating	23-08-10	MT
Stifel Downgrades The Beauty Health Company to Hold From Buy, Adjusts Price Target to $10 From $17	23-06-21	MT
JPMorgan Chase Adjusts Price Target on The Beauty Health to $12 From $13, Maintains Neutral Rating	23-05-26	MT
BNP Paribas Exane Upgrades The Beauty Health to Neutral From Underperform	23-03-20	MT
DA Davidson Adjusts Price Target on Beauty Health to $35 From $32, Keeps Buy Rating	23-03-01	MT
Piper Sandler Adjusts The Beauty Health Price Target to $16 From $15, Maintains Overweight Rating	23-02-28	MT
Cowen Lowers Beauty Health Company's Price Target to $15 From $20, Maintains Outperform Rating	23-02-16	MT
Goldman Sachs Adjusts Beauty Health's Price Target to $19 From $22, Keeps Buy Rating	22-11-23	MT
DA Davidson Adjusts Price Target on The Beauty Health Company to $32 From $31, Maintains Buy Rating	22-11-09	MT
JPMorgan Downgrades Beauty Health to Neutral From Overweight, Adjusts Price Target to $11 From $22	22-11-09	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.22 USD

Average target price

4.49 USD

Spread / Average Target

+39.44%

High Price Target

10.5 USD

Spread / Highest target

+226.09%

Low Price Target

2 USD

Spread / Lowest Target

-37.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering The Beauty Health Company

Canaccord Genuity
TD Cowen
Stifel Nicolaus
Piper Sandler
Jefferies & Co.
William Blair & Co.
Raymond James
JPMorgan Chase
DA Davidson
BNP Paribas Exane
Cowen
Goldman Sachs
Benchmark Capital

Ratings for The Beauty Health Company

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar